These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24594082)

  • 1. An unusual case of influenza-like illness after yellow fever vaccination.
    Lamson DM; Ramani R; Kleabonas M; Metcalfe M; Humphrey C; St George K
    J Clin Virol; 2014 May; 60(1):67-9. PubMed ID: 24594082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza-like illness after yellow fever vaccination.
    Pellegrino P; Carnovale C; Radice S; Clementi E
    J Clin Virol; 2014 Jun; 60(2):181. PubMed ID: 24768323
    [No Abstract]   [Full Text] [Related]  

  • 3. Suspected YF-AND after yellow fever vaccination in Finland.
    Jääskeläinen AJ; Huhtamo E; Kivioja R; Domingo C; Vene S; Kallio-Kokko H; Niedrig M; Tienari PJ; Vapalahti O
    J Clin Virol; 2014 Nov; 61(3):444-7. PubMed ID: 25223921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil.
    Engel AR; Vasconcelos PF; McArthur MA; Barrett AD
    Vaccine; 2006 Apr; 24(15):2803-9. PubMed ID: 16464518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011.
    Jentes ES; Han P; Gershman MD; Rao SR; LaRocque RC; Staples JE; Ryan ET; The Global TravEpiNet Consortium
    Am J Trop Med Hyg; 2013 May; 88(5):954-961. PubMed ID: 23458961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
    Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
    Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-administration of live measles and yellow fever vaccines and inactivated pentavalent vaccines is associated with increased mortality compared with measles and yellow fever vaccines only. An observational study from Guinea-Bissau.
    Fisker AB; Ravn H; Rodrigues A; Østergaard MD; Bale C; Benn CS; Aaby P
    Vaccine; 2014 Jan; 32(5):598-605. PubMed ID: 24325827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.
    Miyaji KT; Luiz AM; Lara AN; do Socorro Souza Chaves T; Piorelli Rde O; Lopes MH; Sartori AM
    Hum Vaccin Immunother; 2013 Feb; 9(2):277-82. PubMed ID: 23291944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
    Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
    Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events following yellow fever vaccination in immunocompromised persons.
    Lara AN; Miyaji KT; Ibrahim KY; Lopes MH; Sartori AMC
    Rev Inst Med Trop Sao Paulo; 2021; 63():e13. PubMed ID: 33656136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
    Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
    Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil.
    Galler R; Pugachev KV; Santos CL; Ocran SW; Jabor AV; Rodrigues SG; Marchevsky RS; Freire MS; Almeida LF; Cruz AC; Yamamura AM; Rocco IM; da Rosa ES; Souza LT; Vasconcelos PF; Guirakhoo F; Monath TP
    Virology; 2001 Nov; 290(2):309-19. PubMed ID: 11883195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
    Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinician's perspective on yellow fever vaccine-associated neurotropic disease.
    Lecomte E; Laureys G; Verbeke F; Domingo Carrasco C; Van Esbroeck M; Huits R
    J Travel Med; 2020 Nov; 27(7):. PubMed ID: 32965473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse event reports following yellow fever vaccination, 2007-13.
    Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
    J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance for yellow Fever virus in non-human primates in southern Brazil, 2001-2011: a tool for prioritizing human populations for vaccination.
    Almeida MA; Cardoso Jda C; Dos Santos E; da Fonseca DF; Cruz LL; Faraco FJ; Bercini MA; Vettorello KC; Porto MA; Mohrdieck R; Ranieri TM; Schermann MT; Sperb AF; Paz FZ; Nunes ZM; Romano AP; Costa ZG; Gomes SL; Flannery B
    PLoS Negl Trop Dis; 2014 Mar; 8(3):e2741. PubMed ID: 24625681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.